Showing results (81-90 of 97) with videos related to
Sort By:
Pageof 10
Frontline Gastroenterology|April 29, 2021
IBD in pregnancy: recent advances, practical managementChristian P Selinger, Catherine Nelson-Piercy, Aileen Fraser, et al.Inflammatory Bowel Diseases|July 4, 2014
Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn's diseaseViraj C Kariyawasam, Christian P Selinger, Peter H Katelaris, et al.Journal of Crohn'S & Colitis|March 20, 2020
Knowledge and Attitudes Towards Pregnancy in Females with Inflammatory Bowel Disease: An International, Multi-centre StudyRobyn Laube, Yunki Yau, Christian P Selinger, et al.Journal of Crohn'S & Colitis|January 23, 2026
Comparative analysis of inflammatory bowel disease patient and service reported quality of care using 2019 and 2023 UK benchmarking data from more than 26,000 adult patient respondents and 154 IBD servicesA Barney Hawthorne, Paul Christiansen, Ian Arnott, et al.Frontline Gastroenterology|August 15, 2023
Establishing key performance indicators for inflammatory bowel disease in the UKMohammed Nabil Quraishi, Elizabeth Dobson, Rachel Ainley, et al.Alimentary Pharmacology & Therapeutics|June 30, 2022
Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patientsA Barney Hawthorne, Jackie Glatter, Jonathan Blackwell, et al.Inflammatory Bowel Diseases|January 1, 2019
Comorbidities Rather Than Age Are Associated With the Use of Immunomodulators in Elderly-onset Inflammatory Bowel DiseaseViraj C Kariyawasam, Shin Kim, Fadi H Mourad, et al.Frontline Gastroenterology|March 17, 2022
Risk stratifying gastric ulcers: development and validation of a scoring systemWilliam M Brindle, Rebecca K Grant, Marianne Smith, et al.Alimentary Pharmacology & Therapeutics|October 10, 2019
Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patientsChristian P Selinger, Gareth C Parkes, Ash Bassi, et al.Alimentary Pharmacology & Therapeutics|December 22, 2021
A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study IIMarco Vincenzo Lenti, Vivien Dolby, Tanya Clark, et al.Pageof 10